Document text
Principal Investigator: Gloria David
Organization: RHO FEDERAL SYSTEMS DIVISION, INC.
Fiscal Year: 2021
Award: $15,843,849
Funding agency: National Institute of Allergy and Infectious Diseases
PROJECT SUMMARY / ABSTRACT
The SARS-CoV-2 virus has triggered a world-wide pandemic with over 28 million cases and more than
500,000 deaths in the United States as of March 1, 2021 (Centers for Disease Control and Prevention, COVID
Data Tracker). The Food and Drug Administration (FDA) has given Emergency Use Authorization (EUA) to two
mRNA vaccines, the Pfizer-BioNTech COVID-19 Vaccine and the Moderna COVID-19 Vaccine. Both vaccines
use the new mRNA lipid nanoparticle delivery system and have been proven to be strikingly effective in
preventing disease in large clinical trials.
Since introduction of these vaccines in a wider population, there have been reports of severe allergic reactions
to vaccination with these products. According to published sources, the incidence rate of anaphylaxis for the
Pfizer-BioNTech COVID-19 Vaccine is estimated at 10/1,000,000 vaccine doses, which is approximately 10-
fold higher than the rate typically seen with commonly used vaccines, and the rate of anaphylaxis for the
Moderna COVID-19 Vaccine has been reported as 2.5/1,000,000. The majority of these reactions have
occurred in individuals with an allergic background and a large number in individuals with a history of
anaphylaxis.
The purpose of this project is to provide support for Rho Federal Systems Division to serve as the Statistical
and Clinical Coordinating Center for protocol development, implementation, data analysis, and reporting of
results for a multicenter, randomized, initially blinded, phase 2 study with two principal aims. The first is to
estimate the proportions of systemic allergic reactions to the Pfizer-BioNTech and the Moderna COVID-19
vaccines in individuals with a history of severe allergic reactions to foods, venoms, drugs, or vaccines (High-
Allergy [HA]), or a history of mast cell disorders (MCD). The second, if the risk in the HA/MCD population is
demonstrable, is to determine whether the proportions are higher in the HA/MCD population compared to a
non-atopic study population. In the event a significant number of immediate systemic allergic reactions to either
or both vaccines are seen, another focus of this study is to begin evaluating the mechanism(s) of allergic
reactions to the COVID-19 vaccines, and to determine if specific risk factors can be identified by patient history
or biomarker testing.
This information will be crucial to properly advise highly allergic individuals and those with mast cell disorders
regarding these vaccines, to maintain public trust in the safety of these vaccines, and to minimize vaccine
hesitancy for these and future vaccines using this new technology.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><Allergic><Allergic Reaction><Allergic to food><Allergy><Allergy to food><Anaphylactic Reaction><Anaphylactic Shock><Anaphylaxis><BNT162b2><Biological Markers><Blinded><Blood Serum><CDC><COVID><COVID-19><COVID-19 vaccine><COVID-19 virus><COVID19><COVID19 vaccine><COVID19 virus><CV-19><CV19><Centers for Disease Control><Centers for Disease Control and Prevention><Centers for Disease Control and Prevention (U.S.)><Cessation of life><Clinical><Clinical Trials><CoV disease><CoV-2><CoV2><Collection><Data><Data Analyses><Data Analysis><Death><Development><Disease><Disorder><Dose><Drugs><Emerging Communicable Diseases><Emerging Infectious Diseases><Event><Exposure to><FDA EUA><FDA Emergency Use Authorization><Food><Food Allergy><Food Hypersensitivity><Food and Drug Administration><Food and Drug Administration EUA><Food and Drug Administration Emergency Use Authorization><Food or Food Product><Future><Glean><History><Hypersensitivity><Incidence><Individual><Marrow Mast Cell><Medical History><Medication><Messenger RNA><Moderna COVID-19 vaccine><Moderna coronavirus disease 2019 vaccine><NIAID><National Institute of Allergy and Infectious Disease><Patients><Personal Medical History><Personal Medical History Epidemiology><Pfizer-BioNTech COVID-19 vaccine><Pfizer-BioNTech coronavirus disease 2019 vaccine><Pharmaceutic Preparations><Pharmaceutical Preparations><Phase 2 Clinical Trials><Phase II Clinical Trials><Population><Publishing><RNA vaccine><RNA-based vaccine><Randomized><Reaction><Recording of previous events><Reporting><Research><Risk><Risk Factors><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Serum><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Source><Standardization><System><Testing><Time><Tissue Basophils><Tryptase><USFDA><United States><United States Centers for Disease Control><United States Centers for Disease Control and Prevention><United States Food and Drug Administration><Vaccination><Vaccines><Venoms><Virus><Wuhan coronavirus><bio-markers><biologic marker><biomarker><corona virus disease><corona virus disease 2019><corona virus disease 2019 vaccine><coronavirus disease><coronavirus disease 2019><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><data interpretation><design><designing><develop a vaccine><development of a vaccine><developmental><drug/agent><emergency use authorization><hCoV19><hesitant to vaccination><improved><lipid nanoparticle><lung tryptase><mRNA><mRNA vaccine><mRNA-1273><mRNA-based vaccine><mRNA1273><mast cell><mast cell protease II><mast cell tryptase><mastocyte><nCoV2><nano particle delivery><nanoparticle delivered><nanoparticle delivery><new technology><new vaccines><next generation vaccines><novel technologies><novel vaccines><pandemic><pandemic disease><phase 2 study><phase II protocol><phase II study><prevent><preventing><primary end point><primary endpoint><prospective><protocol development><public trust><randomisation><randomization><randomly assigned><rho><skin tryptase><study population><vaccination hesitancy><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine development><vaccine for novel coronavirus><vaccine formulation><vaccine hesitancy><vaccine hesitant><vaccine safety>